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Background and objective
Little information exists on long-term outcome of JDM.
Furthermore, most studies have been conducted in single
centres or have involved a few patients. Objective of the
study is to identify predictors of a poorer long-term out-
come of JDM in a multicenter cohort of patients.
Methods
490 patients with JDM and disease duration > 2 years seen
in 27 centers in 5 countries (Italy, UK, Argentina, Brazil,
Mexico) after 1980 were identified. Outcomes included
muscle weakness (MMT), continued activity (DAS),
cumulative damage (MDI), calcinosis, lipodystrophy,
functional impairment (CHAQ), and health-related qual-
ity of life (HRQL) impairment (CHQ). Predictors
included: continent (Europe vs. Latin America), gender,
year of onset, onset age, onset type (acute vs. insidious),
onset manifestations, severity of muscle/skin manifesta-
tions at onset, and course type (monocyclic, polycyclic,
chronic continuous).
Results
Table 1 shows significant predictors for each outcome.
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Table 1: 
(*At onset) M. weak'ss Cont'd activity Damage Funct. Impairm'nt HRQL Impairm'nt
Female sex + - - + -
Onset after 2000 + - - - -
Onset age < 5 yrs - - - - -
Onset type - + - - +
Dysphonia* + - - - -
Mm/skin severity* - - - - +
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Conclusion
The chronic continuous course predicted all outcomes,
which highlights the critical need for treatments and treat-
ment strategies that have the ability to better control dis-
ease activity over time.